Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 73-82 , March 2009

Targeting of albumin-embedded paclitaxel nanoparticles to tumors

  • Priya Prakash Karmali, PhD

      Affiliations

    • Vascular Mapping Center, Burnham Institute for Medical Research at UCSB, University of California, Santa Barbara, California, USA
    • Cancer Research Center, Burnham Institute for Medical Research, La Jolla, California, USA
    • ,
  • Venkata Ramana Kotamraju, PhD

      Affiliations

    • Vascular Mapping Center, Burnham Institute for Medical Research at UCSB, University of California, Santa Barbara, California, USA
    • Cancer Research Center, Burnham Institute for Medical Research, La Jolla, California, USA
    • ,
  • Mark Kastantin, SB

      Affiliations

    • Department of Chemical Engineering and Materials Research Laboratory, University of California, Santa Barbara, California, USA
    • ,
  • Matthew Black, BS

      Affiliations

    • Department of Chemical Engineering and Materials Research Laboratory, University of California, Santa Barbara, California, USA
    • ,
  • Dimitris Missirlis, PhD

      Affiliations

    • Department of Chemical Engineering and Materials Research Laboratory, University of California, Santa Barbara, California, USA
    • ,
  • Matthew Tirrell, PhD

      Affiliations

    • Department of Chemical Engineering and Materials Research Laboratory, University of California, Santa Barbara, California, USA
    • ,
  • Erkki Ruoslahti, MD, PhD

      Affiliations

    • Vascular Mapping Center, Burnham Institute for Medical Research at UCSB, University of California, Santa Barbara, California, USA
    • Cancer Research Center, Burnham Institute for Medical Research, La Jolla, California, USA
    • Corresponding Author InformationCorresponding author. Burnham Institute for Medical Research at UCSB, University of California, Santa Barbara, California 93106-9610, USA.

Received 19 June 2008 ,Accepted 30 July 2008.

References 

  1. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990;9:253–266
  2. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999;5:1359–1364
  3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  4. Ruoslahti E. Specialization of tumor vasculature. Nat Rev Cancer. 2002;2:83–90
  5. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377–380
  6. Hoffman JA, Giraudo E, Singh M, Zhang L, Inoue M, Porkka K, et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell. 2003;4:383–391
  7. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2003;4:393–403
  8. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med. 2002;8:751–755
  9. Pilch J, Brown DM, Komatsu M, Jarvinen TA, Yang M, Peters D, et al. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci U S A. 2006;103:2800–2804
  10. Ruoslahti E, Duza T, Zhang L. Vascular homing peptides with cell-penetrating properties. Curr Pharm Des. 2005;11:3655–3660
  11. Simberg D, Duza T, Park JH, Essler M, Pilch J, Zhang L, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A. 2007;104:932–936
  12. Zhang L, Giraudo E, Hoffman JA, Hanahan D, Ruoslahti E. Lymphatic zip codes in premalignant lesions and tumors. Cancer Res. 2006;66:5696–5706
  13. Dvorak HF, Senger DR, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science. 1985;227:1059–1061
  14. Ghebrehiwet B, Lim BL, Peerschke EI, Willis AC, Reid KB. Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular “heads” of C1q. J Exp Med. 1994;179:1809–1821
  15. Fogal V, Zhang L, Ruoslahti E. Mitochondrial/cell surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res. 2008;68:7210–7218
  16. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A. 2002;99:12617–12621
  17. von Maltzahn G, Ren Y, Park J-H, Min D-H, Kotamraju VR, Jayakumar J, et al. In vivo tumor cell targeting with “click” nanoparticles. Bioconjug Chem. 2008;19:1570–1578
  18. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–7803
  19. Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A. 2004;101:9381–9386
  20. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317–1324
  21. Arleth L, Ashok B, Onyuksel H, Thiyagarajan P, Jacob J, Hjelm RP. Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media. Langmuir. 2005;21:3279–3290
  22. Tu RS, Tirrell M. Bottom-up design of biomimetic assemblies. Adv Drug Deliv Rev. 2004;56:1537–1563
  23. Rosenberg AGK, Studier FW, McCormick M, Berg J, Novy R, Mierendorf R. T7Select® Phage Display System: a powerful new protein display system based on bacteriophage T7. Innovations. 1996;6:1–6Available at: http://www.emdbiosciences.com/docs/NDIS/inno06-000.pdf
  24. Park J-H, von Maltzberg G, Zhang L, Schwartz MP, Ruoslahti E, Bhatia SN, et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv Mater. 2008;20:1630–1635
  25. Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev. 2004;23:293–310
  26. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis. 2003;20:237–250
  27. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007;26:319–331
  28. Langel U. Cell-penetrating peptides: processes and applications. Boca Raton (Fla): CRC Press; 2002;
  29. Zorko M, Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev. 2005;57:529–545
  30. Vives E. Present and future of cell-penetrating peptide mediated delivery systems: “is the Trojan horse too wild to go only to Troy?”. J Control Release. 2005;109:77–85
  31. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806–813

 This work was supported by National Cancer Institute grants CA119335, CA124427, CA115410, CA104898, and, in part, National Heart, Lung and Blood Institute grant HL080718 and MRSEC Program of the National Science Foundation under Award DMR05-20415.

PII: S1549-9634(08)00124-X

doi: 10.1016/j.nano.2008.07.007

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 73-82 , March 2009

Article Tools

* Image Usage & Resolution